STAT+: FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy

An FDA advisory panel unanimously endorsed Moderna's mRNA flu vaccine, concluding its benefits outweigh risks for adults aged 50-64 and those 65+. The FDA may license it via traditional and accelerated pathways, with existing vaccines having used similar routes. Wellington Sun, a former FDA employee who later worked for Moderna, commented on accelerated pathways during the meeting.